Ingredient Science · Polydeoxyribonucleotide
What PDRN actually is, why the biology works, and the one delivery context where topical application approaches the efficacy of an injectable.
PDRN — polydeoxyribonucleotide — is a low-molecular-weight DNA fragment derived from salmon sperm. It became the defining aesthetic ingredient of the mid-2020s, largely driven by the explosion of Rejuran and Korean skin booster culture reaching Western aesthetics. By 2026 it is routinely listed alongside hyaluronic acid and GHK-Cu as a benchmark post-procedure active.
The problem is the mechanism that makes PDRN work — activating A2A purinergic receptors deep in the dermis — also makes it almost impossible to deliver topically. Rejuran injectables work because they bypass the skin barrier entirely. Most PDRN serums on the market sit on top of the epidermis, absorbing at sub-therapeutic concentrations, doing very little.
There is one exception. In the 4-hour window immediately after microneedling, the stratum corneum is perforated by hundreds of temporary microchannels. High-molecular-weight molecules that are normally blocked — including PDRN — can now penetrate into the dermis. This guide explains the science behind that window, and why post-microneedling PDRN delivery is the only topical context where the clinical evidence becomes relevant.
Polydeoxyribonucleotide is a mixture of low-molecular-weight DNA fragments. In medical and cosmetic applications, it is derived from the purified sperm cells of Oncorhynchus mykiss (rainbow trout) or Oncorhynchus keta (chum salmon). The source material is selected because salmon DNA shares a high degree of structural homology with human DNA — which is what gives PDRN its biological activity in human tissue.
The manufacturing process involves extracting and fragmenting the DNA into smaller chains, then subjecting it to a series of enzymatic and physical purification steps to remove proteins, lipids, and cellular debris. The resulting molecule is a pure polydeoxyribonucleotide — not a cellular extract, not a whole DNA molecule, but a defined, partially depolymerised DNA fragment.
The key functional property: PDRN acts as a ligand for the adenosine A2A receptor, expressed on dermal fibroblasts, endothelial cells, and immune cells. Activation of this receptor initiates a cascade of tissue repair, anti-inflammatory, and pro-anabolic signalling. This mechanism — not any structural DNA-repair effect — is the primary reason PDRN has clinical value in skin.
When PDRN binds to the A2A receptor on dermal fibroblasts, it triggers a cAMP–PKA signalling cascade — the same pathway involved in tissue repair after injury. The downstream effects are simultaneously anti-inflammatory and pro-anabolic, which is unusual among cosmetic actives. Most ingredients do one or the other.
Pro-anabolic effects: A2A activation promotes fibroblast proliferation, collagen type I synthesis, and elastin production. Cavallini et al. confirmed histologically new collagen and elastin formation in human skin following PDRN treatment. Polito et al. demonstrated direct A2A-dependent upregulation of collagen I in fibroblast cultures.
Anti-inflammatory effects: PDRN suppresses NF-κB, reduces TNF-α, IL-1β, and IL-6, and has been shown to modulate VEGF in a tissue-context-dependent way — pro-angiogenic in wound healing environments, anti-inflammatory in intact tissue. Lee et al. showed superior reduction in post-procedure erythema and downtime compared to HA alone.
DNA repair activity: PDRN fragments can act as a substrate for the nucleoside salvage pathway — providing purine bases (adenosine, guanosine) that cells use to repair DNA damage from UV radiation and procedure-induced stress. Guida et al. demonstrated accelerated wound healing in models combining PDRN's salvage pathway activity with A2A signalling.
A2A receptor activation → cAMP–PKA cascade → fibroblast proliferation + collagen I / elastin synthesis. Parallel NF-κB suppression → TNF-α / IL-1β / IL-6 reduction. Nucleoside salvage → DNA repair substrate provision.
The 500 Da rule is the fundamental constraint of topical skincare: molecules above approximately 500 Daltons do not readily cross the intact stratum corneum. It is not a hard cutoff — very lipophilic molecules can exceed this — but for hydrophilic polydeoxyribonucleotides, the rule is stringent.
PDRN's molecular weight ranges from ~50,000 to 2,000,000 Da — 100 to 4,000 times the passive penetration threshold. Applied to intact skin, dermal delivery is estimated at less than 0.1% of the applied dose. The molecule sits on the epidermis, interacts with surface receptors at subtherapeutic concentrations, and is largely washed off or shed with natural desquamation.
This is why injectable PDRN — Rejuran, Juvelook, PN HP, and similar products — outperforms topical PDRN in virtually every clinical comparison. Injectables bypass the barrier entirely and deliver the molecule directly to the target tissue. Comparing a Rejuran injection to a PDRN serum on intact skin is not a meaningful comparison.
Most "PDRN serums" on the market are therefore primarily efficacy claims backed by ingredient presence, not functional dose delivery. The A2A mechanism is real and well-evidenced — but only at the concentration and tissue depth where the molecule can actually engage its receptor.
Microneedling creates hundreds to thousands of temporary micro-channels in the stratum corneum and epidermis. These channels are not simple holes — they are complex aqueous pathways through a normally lipid-rich barrier, temporarily disrupting the architecture that blocks high-molecular-weight hydrophilic molecules.
The absorption increase is substantial. Kim et al. (PMC4590292) demonstrated a 20–55× increase in transdermal flux for hydrophilic peptides after microneedle treatment compared to intact skin. Mohammed et al. (PMC4102460) confirmed 2–22-fold signal improvement for cosmeceutical peptide delivery into ex vivo human skin. Kalluri et al. (PMC3160154) established that skin barrier recovery begins 4–5 hours post-poration and reaches full closure at 12–18 hours depending on needle depth.
For PDRN specifically, the micro-channel pathway changes the delivery context entirely. High-molecular-weight fragments that are completely blocked by intact skin can now transit into the upper dermis via the aqueous channels. The 4-hour absorption window is the critical parameter: CUVA R1 is designed to be applied within 5 minutes of the procedure, using the full window before progressive barrier recovery begins to close channels.
The practical implication: post-microneedling topical PDRN at 1%+ concentration, applied during the open-channel window, delivers a dermal dose that approaches the lower range of injectable PDRN. It is not identical — injectable delivery is still more precise and predictable — but the gap narrows dramatically from the <0.1% passive baseline.
Channels open: immediately post-procedure. Peak permeability: 0–60 minutes. Barrier recovery begins: 4–5 hours. Full closure: 12–18 hours. Optimal application: within 5 minutes of completing needling.
Activates A2A receptor → cAMP–PKA cascade → fibroblast proliferation + collagen I/elastin synthesis. Simultaneous NF-κB suppression reduces post-procedure inflammation. Primary mechanism: cellular signalling and anti-inflammatory control.
Activates lysyl oxidase (LOX) for collagen and elastin cross-linking. Upregulates 4,000+ genes toward repair phenotype. TGF-β receptor signalling for structural ECM synthesis. Primary mechanism: tissue remodeling and matrix structural integrity.
These mechanisms do not compete. PDRN operates primarily via the purinergic A2A pathway; GHK-Cu operates via copper enzyme activation and fibroblast gene modulation. They target different receptors, activate different downstream cascades, and produce complementary outcomes — PDRN driving cellular proliferation and acute repair signalling, GHK-Cu driving structural matrix remodeling. Combining them in a single post-microneedling ampoule is the logical clinical formulation strategy.
All references cite published peer-reviewed studies on ingredient mechanisms under specific experimental or clinical parameters. Results are not a guarantee of product outcomes. CUVA products are cosmetics regulated under EU Regulation EC 1223/2009.
The PDRN category has significant quality variance. Most products contain the ingredient at sub-threshold concentrations, in non-sterile formats, and are positioned for intact-skin use where delivery is negligible. Four criteria separate clinically relevant PDRN products from label-claim products:
CUVA R1 contains 1% PDRN (10,000 ppm) combined with 2% GHK-Cu in a sterile single-use ampoule — formulated specifically for post-microneedling application. Each ingredient is at clinical threshold. Nothing is present for label effect.
Trade enquiries: [email protected]